Domain Not Resolving

DNSSEC

Google Maps

IPv6

Google Maps API

Google Maps for Work

Mobile Optimized

Akamai Hosted

Drupal

Adobe Dynamic Tag Management

Healthcare

Baisong Mei, MD PhD

EVP, CTO and CBO

Bruce Eaton

Executive Vice President & General Counsel

Charlene Stern

Chief Human Resources Officer

Clare Carmichael

Chief Business Officer

Gad Berdugo

President and CEO

Gilmore ONeill

Chairman, President, and CEO

James Mullen

Executive Assistant to Chief Financial Officer

Kristen George

Executive Vice President and Chief Medical Officer

Lisa Michaels

Chief Scientific Officer/Executive Vice-President

Mark Shearman

Andrew Hirsch

Alexis Borisy

Douglas Cole

Meeta Chatterjee

Terrance McGuire

Kevin Bitterman

Interim President

Executive Chairman

Mark S.Shearman

Chief Scientific Officer & Executive Vice-President

Charles Albright

Executive Vice President and Chief Scientific Officer

Linda C. Burkly

Executive Vice President & Chief Scientific Officer

John Follit

Associate Director - iPSC Engineering

New England Companies With More Than 10 Employees (Top 10K)

United States Companies With Less Than $1B in Revenue (Top 10K)

Health Care Companies With Less Than $500M in Revenue (Top 10K)

East Coast Companies With Less Than $50M in Revenue (Top 10K)

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Post-IPO Equity - Editas Medicine

Boris Nikolic

Series B - Editas Medicine

Juno Therapeutics

Venture Round - Editas Medicine

Flagship Pioneering

Polaris Partners

Third Rock Ventures

Series A - Editas Medicine

Computer and Software Services and Scientific Services

Cambridge

Massachusetts

United States

North America

Editas Medicine

Biotech Alert: Searches spiking for these stocks today

Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio

Sickle Cell Disease Market Reach USD 12.38 Bn by 2032, Set to Grow Remarkable CAGR of 20.00% from 2024-2032

Editas Medicine to Participate in Upcoming Investor Conferences

Duchenne Muscular Dystrophy (DMD) Therapeutics Market to Grow by USD 4.37 Billion from 2024-2028, Driven by High Unmet Needs and AI-Powered Market Evolution - Technavio

Raymond James downgrades Editas on extended development timelines

Raymond James gets more bearish on Editas Medicine, downgrades shares

Editas Medicine Announces Q3 Results And Business Updates

Editas prioritizes in vivo therapies, seeks reni-cel partner

Editas Medicine achieves in vivo preclinical proof of concept of HSPC editing

Reni-cel is a gene editing medicine under investigation for severe sickle cell disease and transfusion-dependent beta thalassemia, editing CD34+ cells at the HBG1 and HBG2 promoters.

EDIT-101 is a gene editing medicine designed to treat blindness due to Leber congenital amaurosis 10 by repairing the IVS26 CEP290 mutant allele.

A platform utilizing CRISPR technology for gene editing, aiming to develop medicines for a range of diseases including ocular, blood diseases, and cancer.

Development of ex vivo gene editing medicines, where cells are edited outside the body and then administered to patients.

Development of in vivo gene editing medicines, focusing on editing genes inside the body for various diseases.

Spain

Europe

India

Asia

Canada

Japan

HTML5

GoDaddy Premium DNS

Wordpress

GoDaddy

Google Fonts

Google Analytics

F5 NGINX

Adobe Fonts

jQuery

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

news impact assignment basic	general	Mar 8, 2024 8:33 PM	bf22ad31
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 8:33 PM	48ab30a9
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	4a9a2e65
crunchbase profile	general	Nov 22, 2024 9:32 AM	d5301863
li profile	general
translate crunchbase fundingrounds	general	Nov 22, 2024 2:06 PM	0311a1b0
peers	general
news basic	general	Mar 8, 2024 8:33 PM	68b827eb
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:EDITASMEDICINE

Editas Medicine

Last Close

2.37

22/11 21:00

Market Cap

417.77M

Beta: -

Volume Today

2.25M

Avg: -